DelveInsight’s, “Acute Kidney Injury Pipeline Insight 2026” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Acute Kidney Injury pipeline landscape. It covers the Acute Kidney Injury Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acute Kidney Injury Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Acute Kidney Injury Pipeline? Click here to explore the therapies and trials making headlines @ Acute Kidney Injury Pipeline Outlook Report

Key Takeaways from the Acute Kidney Injury Pipeline Report

• On April 13, 2026- Novartis Pharmaceuticals initiated a Ph2b study is to characterize the dose-response relationship and to evaluate the safety and efficacy of three different single doses of TIN816 in hospitalized adult participants in an intensive care setting with a diagnosis of sepsis-associated acute kidney injury (SA-AKI).
• On April 13, 2026- Noorik Biopharmaceuticals AG conducted a phase II clinical trial is to test whether the administration of low doses of ambrisentan can help patients with Hepatorenal Syndrome and to determine if it is safe. Ambrisentan is a drug that is approved for the treatment of high blood pressure in the lungs at higher doses.
• On April 13, 2026- Vantive Health LLC announced a study are: 1) to confirm the safety of Prismocitrate 18 in patients receiving CRRT using continuous venovenous hemodiafiltration (CVVHDF) or continuous venovenous hemofiltration (CVVH) and 2) to observe that the software and interface for the PrisMax System Version 3.x with calcium line accessory allows for implementation of regional citrate anticoagulation (RCA) (citrate and calcium dosing) during CRRT with Prismocitrate 18 and intended prescription.
• On April 13, 2026- Alexion Pharmaceuticals Inc. initiated a phase 3 study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.
• DelveInsight’s Acute Kidney Injury Pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Acute Kidney Injury treatment.
• The leading Acute Kidney Injury Companies such as AM-Pharma Holding, Guard Therapeutics AB, Novartis Pharmaceuticals, Faron Pharmaceuticals, Kantum Pharma, Revelation Biosciences, Arch Biopartners Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Metro International Biotech, LLC, River 2 Renal Corp., Guard Therapeutics AB, Sentien Biotechnologies, Kelifarma and others.
• Promising Acute Kidney Injury Therapies such as Conestat alfa (Ruconest®), Neseritide, GDC-8264, THR-184, ABT-719, QPI-1002, Ciclosporin and others.

Want to know which companies are leading innovation in Acute Kidney Injury? @ Acute Kidney Injury Clinical Trials Assessment

The Acute Kidney Injury Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Acute Kidney Injury Pipeline Report also highlights the unmet needs with respect to the Acute Kidney Injury.

Acute Kidney Injury Overview

Acute kidney injury (AKI), also known as acute renal failure (ARF), is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. AKI causes a build-up of waste products in blood and makes it hard for kidneys to keep the right balance of fluid in body. AKI can also affect other organs such as the brain, heart, and lungs. Acute kidney injury is common in patients who are in the hospital, in intensive care units, and especially in older adults. There are rarely any symptoms until the condition has progressed to a late stage. However, if there are symptoms, the most common one is a decrease in urine output. Doctors diagnose acute kidney injury by measuring the level of creatinine in the blood. (Creatinine is a chemical waste product removed by the body entirely by the kidneys. If the kidneys are not working properly, there will be an increase in levels in the blood).

Acute Kidney Injury Emerging Drugs Profile

• Ilofotase alfa: AM-Pharma Holding

Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase that has been shown to be stable and highly active in multiple clinical trials. The recombinant enzyme displays exquisite activity towards dephosphorylating and detoxifying damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS), ATP, ADP and other extracellular substrates that drive acute inflammation, coagulation and microvascular ischemia found in kidney following sepsis or ischemia-induced damage. Currently, the drug is in Phase III stage of its development for the treatment of acute kidney injury.

• RMC-035: Guard Therapeutics AB

Guard Therapeutics is developing RMC-035 (ROSgard), a biological drug candidate that utilizes one of the body’s most powerful and universal protections against oxidative stress. RMC-035 is naturally designed to “”target”” the kidneys, allowing RMC-035 to be present when the kidneys are attacked by oxidative stress. Treatment with RMC-035 has the potential to save lives and prevent the risk of both acute and chronic kidney damage with subsequent serious consequences due to impaired kidney function, such as life-sustaining dialysis treatment. Currently, it is in Phase II stage of clinical trial evaluation to treat Acute Kidney Injury.

• KELI-101: Kelifarma

KELI‑101 is an allogeneic placental mesenchymal stromal cell therapy under development by UAB Kelifarma (also referred to as Keli Therapeutics) for the preemptive treatment of acute kidney injury (AKI) following cardiac surgery. It harnesses placenta-derived mesenchymal cells to modulate inflammation, enhance tissue repair, and protect renal structure and function. The program is now in a Phase Ib/II clinical trial (NCT06678399), scheduled to begin around April 2025 and complete primary evaluation by October 2026. Early preclinical studies have shown improvements in survival, diuresis, biochemical markers, and prevention of structural kidney damage in animal models. Currently, it is in Phase I/II stage of clinical trial evaluation to treat Acute Kidney Injury.

If you’re tracking ongoing Acute Kidney Injury Clinical trials, this press release is a must-read @ Acute Kidney Injury Treatment Drugs

The Acute Kidney Injury Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Acute Kidney Injury with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Kidney Injury Treatment.
• Acute Kidney Injury Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acute Kidney Injury Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Kidney Injury market.

Acute Kidney Injury Companies

AM-Pharma Holding, Guard Therapeutics AB, Novartis Pharmaceuticals, Faron Pharmaceuticals, Kantum Pharma, Revelation Biosciences, Arch Biopartners Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Metro International Biotech, LLC, River 2 Renal Corp., Guard Therapeutics AB, Sentien Biotechnologies, Kelifarma and others.

Acute Kidney Injury Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Acute Kidney Injury Products have been categorized under various Molecule types such as,

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Acute Kidney Injury Pipeline Report @ Acute Kidney Injury Market Drivers and Barriers, and Future Perspectives

Scope of the Acute Kidney Injury Pipeline Report

• Coverage- Global
• Acute Kidney Injury Companies- AM-Pharma Holding, Guard Therapeutics AB, Novartis Pharmaceuticals, Faron Pharmaceuticals, Kantum Pharma, Revelation Biosciences, Arch Biopartners Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Metro International Biotech, LLC, River 2 Renal Corp., Guard Therapeutics AB, Sentien Biotechnologies, Kelifarma and others.
• Acute Kidney Injury Therapies- Conestat alfa (Ruconest®), Neseritide, GDC-8264, THR-184, ABT-719, QPI-1002, Ciclosporin and others.
• Acute Kidney Injury Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Acute Kidney Injury Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Acute Kidney Injury Treatment landscape in this detailed analysis @ Acute Kidney Injury Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Acute Kidney Injury: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Acute Kidney Injury– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Ilofotase alfa: AM-Pharma Holding
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. RMC-035: Guard Therapeutics AB
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. KELI-101: Kelifarma
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Acute Kidney Injury Key Companies
21. Acute Kidney Injury Key Products
22. Acute Kidney Injury- Unmet Needs
23. Acute Kidney Injury- Market Drivers and Barriers
24. Acute Kidney Injury- Future Perspectives and Conclusion
25. Acute Kidney Injury Analyst Views
26. Acute Kidney Injury Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/acute-kidney-injury-aki-pipeline-insight